Wall Street Zen Upgrades Context Therapeutics (NASDAQ:CNTX) to Hold

Context Therapeutics (NASDAQ:CNTX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday.

A number of other research analysts also recently weighed in on the stock. HC Wainwright upped their price objective on shares of Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Thursday, November 6th. JonesTrading initiated coverage on Context Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Context Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $6.00.

Context Therapeutics Price Performance

NASDAQ:CNTX opened at $2.33 on Monday. The company has a 50 day moving average price of $1.70 and a 200-day moving average price of $1.26. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.85. The firm has a market cap of $214.08 million, a price-to-earnings ratio of -9.71 and a beta of 1.94.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Clear Harbor Asset Management LLC raised its stake in Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after purchasing an additional 35,000 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics during the 3rd quarter worth approximately $100,000. State Street Corp raised its position in shares of Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after buying an additional 13,000 shares during the period. Renaissance Technologies LLC lifted its holdings in Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after acquiring an additional 188,202 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after acquiring an additional 134,449 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.